214 related articles for article (PubMed ID: 12722044)
1. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient.
Kosch M; Barenbrock M; Suwelack B; Schaefer RM; Rahn KH; Hausberg M
Am J Kidney Dis; 2003 May; 41(5):1088-96. PubMed ID: 12722044
[TBL] [Abstract][Full Text] [Related]
2. Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation.
Hausberg M; Kosch M; Stam F; Heidenreich S; Kisters K; Rahn KH; Barenbrock M
Kidney Int; 2001 Apr; 59(4):1473-9. PubMed ID: 11260410
[TBL] [Abstract][Full Text] [Related]
3. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
Holdaas H; Hartmann A; Stenstrøm J; Dahl KJ; Borge M; Pfister P
Am J Cardiol; 1995 Jul; 76(2):102A-106A. PubMed ID: 7604781
[TBL] [Abstract][Full Text] [Related]
4. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine.
Goldberg RB; Roth D
Am J Cardiol; 1995 Jul; 76(2):107A-109A. PubMed ID: 7604782
[TBL] [Abstract][Full Text] [Related]
5. Effects of fluvastatin, an HMG-CoA reductase inhibitor, on serum levels of interleukin-18 and matrix metalloproteinase-9 in patients with hypercholesterolemia.
Leu HB; Chen JW; Wu TC; Ding YA; Lin SJ; Charng MJ
Clin Cardiol; 2005 Sep; 28(9):423-8. PubMed ID: 16250265
[TBL] [Abstract][Full Text] [Related]
6. Vasodilatory capacity of forearm resistance vessels is augmented in hypercholesterolemic patients after treatment with fluvastatin.
Schobel HP; Schmieder RE
Angiology; 1998 Sep; 49(9):743-8. PubMed ID: 9756426
[TBL] [Abstract][Full Text] [Related]
7. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data.
Holdaas H; Fellström B; Holme I; Nyberg G; Fauchald P; Jardine A; Grönhagen-Riska C; Madsen S; Neumayer HH; Cole E; Maes B; Weinreich T; Olsson AG; Pedersen TR; Benghozi R; Hartmann A;
J Cardiovasc Risk; 2001 Apr; 8(2):63-71. PubMed ID: 11324372
[TBL] [Abstract][Full Text] [Related]
8. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.
Aviram M; Hussein O; Rosenblat M; Schlezinger S; Hayek T; Keidar S
J Cardiovasc Pharmacol; 1998 Jan; 31(1):39-45. PubMed ID: 9456275
[TBL] [Abstract][Full Text] [Related]
9. Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation.
Asberg A; Holdaas H; Jardine AG; Edvardsen C; Hartmann A
Clin Transplant; 2003 Aug; 17(4):385-90. PubMed ID: 12868997
[TBL] [Abstract][Full Text] [Related]
10. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease.
Eichstädt HW; Eskötter H; Hoffman I; Amthauer HW; Weidinger G
Am J Cardiol; 1995 Jul; 76(2):122A-125A. PubMed ID: 7604786
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial.
Zavoral JH; Haggerty BJ; Winick AG; Bergmann SD
Am J Cardiol; 1995 Jul; 76(2):37A-40A. PubMed ID: 7604795
[TBL] [Abstract][Full Text] [Related]
12. Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients.
Inoue T; Hayashi M; Takayanagi K; Morooka S
Atherosclerosis; 2002 Feb; 160(2):369-76. PubMed ID: 11849660
[TBL] [Abstract][Full Text] [Related]
13. Effects of statins on vascular endothelial function in hypercholesterolemic patients with type 2 diabetes mellitus: fluvastatin vs. rosuvastatin.
Tomizawa A; Hattori Y; Suzuki K; Okayasu T; Kase H; Satoh H; Kasai K
Int J Cardiol; 2010 Sep; 144(1):108-9. PubMed ID: 19174316
[No Abstract] [Full Text] [Related]
14. Fluvastatin and low-density lipoprotein oxidation in hypercholesterolemic renal transplant patients.
Martínez-Castelao A; Grinyó JM; Fiol C; Castiñeiras MJ; Hurtado I; Gil-Vernet S; Serón D; Porta I; Miñarro A; Villarroya A; Alsina J
Kidney Int Suppl; 1999 Jul; 71():S231-4. PubMed ID: 10412785
[TBL] [Abstract][Full Text] [Related]
15. Is endothelial dysfunction reversible?
Schmieder RE; Schobel HP
Am J Cardiol; 1995 Jul; 76(2):117A-121A. PubMed ID: 7604785
[TBL] [Abstract][Full Text] [Related]
16. Fluvastatin reduces oxidative stress, decreases serum monocyte chemotactic protein-1 level and improves endothelial function in patients with hypercholesterolemia.
Leu HB; Wu CC; Wu TC; Lin SJ; Chen JW
J Formos Med Assoc; 2004 Dec; 103(12):914-20. PubMed ID: 15624040
[TBL] [Abstract][Full Text] [Related]
17. Effects of fluvastatin on hyperlipidemia after renal transplantation: influence of steroid therapy.
Austen JL; Shifrin FA; Bartucci MR; Knauss TC; Schulak JA; Hricik DE
Ann Pharmacother; 1996 Dec; 30(12):1386-9. PubMed ID: 8968448
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine.
Goldberg R; Roth D
Transplantation; 1996 Dec; 62(11):1559-64. PubMed ID: 8970607
[TBL] [Abstract][Full Text] [Related]
19. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
Plosker GL; Wagstaff AJ
Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
[TBL] [Abstract][Full Text] [Related]
20. Preservation of endothelial function by the HMG-CoA reductase inhibitor fluvastatin through its lipid-lowering independent antioxidant properties in atherosclerotic rabbits.
Mitani H; Egashira K; Ohashi N; Yoshikawa M; Niwa S; Nonomura K; Nakashima A; Kimura M
Pharmacology; 2003 Jul; 68(3):121-30. PubMed ID: 12784083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
